A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Neoplasms|Triple-Negative Breast Neoplasm|Triple-Negative Breast Cancer|Triple Negative Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Neoplasms|ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: BIOLOGICAL: Bavituximab|DRUG: Taxane
Sponsor: Peregrine Pharmaceuticals